Creso Pharma (ASX: CPH)
Creso Pharma (ASX: CPH) has become the first ASX listed company to import medicinal cannabis products into Australia under new government legislation, as it looks to capitalize on growing interest and demand.
CPH’s ability to distribute Canadian partner CanniMed®’s products across Australia in authorized pharmacies, via its Australian distributor Health House International, gives the company a big head start and a first mover advantage over other companies in this space.
And with $10.6 million cash at end of last quarter and products at the ready, CPH will look to fast track Australian market penetration, whilst keeping an eye on its global ambitions.
Helping CPH’s push will be newly appointed COO David Russell, a highly experienced pharmaceutical and biotech industry stalwart, who has more than 25 years’ experience with a number of leading global billion dollar companies including Roche, Actelion Pharmaceuticals, Celgene and Novogen.
Mr Russell will provide invaluable insight and direction into go-to-market strategies for CPH and will also be responsible for developing the Australian business and overall commercial strategy for CPH in Australia.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
CPH is full steam ahead as it looks for global distribution channels for an active pipeline of products, concentrating both on animal health and on the human health markets.
Having a first mover product advantage in Australia is just one more step in the company’s journey for global medicinal cannabis dominance.